<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00597220</url>
  </required_header>
  <id_info>
    <org_study_id>FORWARD</org_study_id>
    <nct_id>NCT00597220</nct_id>
  </id_info>
  <brief_title>Randomized Trial to Assess Efficacy of PUFA for the Maintenance of Sinus Rhythm in Persistent Atrial Fibrillation</brief_title>
  <acronym>FORWARD</acronym>
  <official_title>Randomized, Prospective, Placebo-controlled, Multi-center Study to Test the Efficacy of n-3 PUFA for the Maintenance of Normal Sinus Rhythm in Patients With Persistent Atrial Fibrillation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fundacion GESICA</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fundacion GESICA</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To demonstrate that in patients with persistent atrial fibrillation who had recovered normal&#xD;
      sinus rhythm and treated with the best recommended therapies, the addition of 1 gram / daily&#xD;
      of n-3 PUFA is superior to the corresponding placebo for the maintenance of normal sinus&#xD;
      rhythm at one year of follow up.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Atrial fibrillation (AF) impose a substantial and growing economic burden on health care&#xD;
      expenditures. In patients with persistent AF, there are fundamentally two ways to manage the&#xD;
      arrhythmia: to restore and maintain sinus rhythm (rhythm control) or to allow AF to continue&#xD;
      and ensure that the ventricular rate is controlled (rate control). As it has been stated, it&#xD;
      goes without saying that if we could prevent atrial fibrillation (AF) or restore and maintain&#xD;
      sinus rhythm in patients suffering from persistent AF, without any penalties due to the&#xD;
      unwanted effects of drugs or incomplete suppression of AF and its thromboembolic&#xD;
      complications, every physician would do so. Current strategies however, are limited to&#xD;
      achieve such desirable goal. In the last years a growing amount of evidence and attention&#xD;
      regarding the cardio-protective role of Omega 3 fatty acids (n-3 PUFA) became progressively&#xD;
      clear and appealing.&#xD;
&#xD;
      Epidemiological studies and randomized controlled trials confirms the role of n-3 PUFA in&#xD;
      reducing all cause mortality and cardiovascular events mostly in patients at high&#xD;
      cardiovascular risk. These effects seems to be mediated mostly by an anti-arrhythmogenic&#xD;
      effect.&#xD;
&#xD;
      Basic science confirms and extended clinical observations regarding the antiarrhythmogenic&#xD;
      effect of these compounds. Recently both basic research and clinical science suggested a role&#xD;
      of n-3 PUFA for the prevention and treatment of supraventricular arrhythmias, particularly&#xD;
      AF.&#xD;
&#xD;
      The purpose of the study is to show that the addition of n-3 PUFA on the top of the best&#xD;
      recommended therapies can improve the maintenance of normal sinus rhythm in patients with&#xD;
      persistent atrial fibrillation.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>January 2008</start_date>
  <completion_date type="Anticipated">August 2011</completion_date>
  <primary_completion_date type="Anticipated">July 2011</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Survival free of atrial fibrillation</measure>
    <time_frame>12 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of patients in sinus rhythm at the time of each study visit</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of hospitalizations for CV reasons</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of all-cause hospitalizations</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of TE events</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients who die or with non-fatal thromboembolic events</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">1600</enrollment>
  <condition>Atrial Fibrillation</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Omega 3</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Omega 3 (n-3 PUFA)</intervention_name>
    <description>1 gram of n-3 PUFA containing DHA and EPA</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Persistent atrial fibrillation&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Contraindications or known hypersensitivity to n-3 PUFA&#xD;
&#xD;
          -  Current treatment with n-3 PUFA for any reason&#xD;
&#xD;
          -  Heart failure NYHA class IV&#xD;
&#xD;
          -  Coronary artery bypass surgery or valve replacement within the past 3 months&#xD;
&#xD;
          -  Planned cardiac procedures&#xD;
&#xD;
          -  Known sick-sinus syndrome&#xD;
&#xD;
          -  Diagnosis of Wolff-Parkinson-White&#xD;
&#xD;
          -  Clinical significant valvular etiologies&#xD;
&#xD;
          -  Presence of arrhythmia associated with an acute reversible condition&#xD;
&#xD;
          -  Advanced chronic lung disease&#xD;
&#xD;
          -  Contraindications for anticoagulation therapy&#xD;
&#xD;
          -  Pregnancy or lactation&#xD;
&#xD;
          -  Any non cardiac illness associated with a life expectancy of &lt; 2 years&#xD;
&#xD;
          -  Treatment with any investigational agent within 3 month before randomization&#xD;
&#xD;
          -  Any condition that in the opinion of the investigator would jeopardize the evaluation&#xD;
             of efficacy or safety or be associated with poor adherence to the protocol&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hernan C Doval, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Fundacion GESICA</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Gianni Tognoni, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Mario Negri Institute</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Hugo Grancelli, MD</last_name>
    <role>Study Director</role>
    <affiliation>Fundacion GESICA</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Sergio Varini, MD</last_name>
    <role>Study Director</role>
    <affiliation>Fundacion GESICA</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Daniel Nul, MD</last_name>
    <role>Study Director</role>
    <affiliation>Fundacion GESICA</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Alejandro Macchia, MD</last_name>
    <role>Study Director</role>
    <affiliation>Fundacion GESICA</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hospital Alem√°n</name>
      <address>
        <city>Caba</city>
        <state>Buenos Aires</state>
        <zip>1118</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinica Constituyentes</name>
      <address>
        <city>Caba</city>
        <state>Buenos Aires</state>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Complejo Medico Policial Churruca Visca</name>
      <address>
        <city>Caba</city>
        <state>Buenos Aires</state>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fundacion Favaloro</name>
      <address>
        <city>Caba</city>
        <state>Buenos Aires</state>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Evita Pueblo FEDITEC</name>
      <address>
        <city>Lanus</city>
        <state>Buenos Aires</state>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinica y Maternidad Colon</name>
      <address>
        <city>Mar del Plata</city>
        <state>Buenos Aires</state>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Privado de la Comunidad</name>
      <address>
        <city>Mar del Plata</city>
        <state>Buenos Aires</state>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanatorio Parque</name>
      <address>
        <city>Rosario</city>
        <state>Santa Fe</state>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CEMIC (Centro de Educaci√≥n M√©dica e Investigaciones Clinicas Norberto Quirno)</name>
      <address>
        <city>Ciudad Autonoma de Buenos Aires</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinica Romagosa</name>
      <address>
        <city>Cordoba</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Jos√© de San Mart√≠n</name>
      <address>
        <city>Corrientes</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanatorio Integral IOT</name>
      <address>
        <city>Misiones</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centro Cardiovascular Salta</name>
      <address>
        <city>Salta</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Argentina</country>
  </location_countries>
  <verification_date>June 2011</verification_date>
  <study_first_submitted>January 8, 2008</study_first_submitted>
  <study_first_submitted_qc>January 16, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 17, 2008</study_first_posted>
  <last_update_submitted>June 21, 2011</last_update_submitted>
  <last_update_submitted_qc>June 21, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 22, 2011</last_update_posted>
  <responsible_party>
    <name_title>Alejandro Macchia</name_title>
    <organization>Fundacion GESICA</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atrial Fibrillation</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

